Cardiovascular pharmacologyPlatelet Inhibition by Aspirin 81 and 325 mg/day in Men Versus Women Without Clinically Apparent Cardiovascular Disease
Section snippets
Methods
The study sample included 106 unaffected, apparently healthy family members of 65 patients with documented coronary artery disease events before 60 years of age, including brothers and sisters, adult offspring ≥21 years of age, and the co-parent of the adult offspring. Subjects were studied at baseline, after 14 days of aspirin 81 mg/day, and after 14 days of aspirin 325 mg/day (Figure 1). Subjects were recruited from the Genetic Study of Aspirin Responsiveness (GeneSTAR), an ongoing study
Results
Women enrolled in the study were older, had lower hematocrit levels, and higher platelet counts, serum fibrinogen levels, and high-density lipoprotein cholesterol levels (Table 1). There were no significant differences between men and women with respect to other cardiovascular risk factors. All patients completed the study, with no dropouts. Pill counts and self-reported nonadherence showed that almost 94% of subjects took >80% of the prescribed doses of aspirin. There were no differences
Discussion
In this study comparing 2 low doses of aspirin in clinically unaffected subjects from families with premature coronary artery disease, we found baseline differences in platelet function between men and women that became even more prominent after aspirin therapy. Aspirin in either dose showed less suppression in collagen and ADP-induced platelet activation. Women were more reactive in these pathways than men after aspirin 81 and 325 mg/day, with no statistically significant incremental
References (14)
Aspirin to prevent heart attack and stroke: what's the right dose?
Am J Med
(2006)- et al.
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialHOT Study Group
Lancet
(1998) - et al.
Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients
J Thromb Haemost
(2006) - et al.
Sex differences in platelet reactivity and response to low-dose aspirin therapy
JAMA
(2006) - et al.
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials
JAMA
(2006) - et al.
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
JAMA
(2003) - et al.
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Clin Chem
(1972)
Cited by (43)
Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients with Versus Without Chronic Kidney Disease
2016, American Journal of CardiologyCitation Excerpt :Data on the following variables were obtained: (1) diabetes mellitus (defined as glycosylated hemoglobin level ≥6.3%, fasting blood glucose level ≥126 mg/dl, or use of hypoglycemic agents); (2) hyperlipidemia (use of antilipid medications, total cholesterol ≥240 mg/dl, or serum low-density lipoprotein ≥160 mg/dl), current smoking (any cigarette smoking in the past 30 days); and (3) hypertension (an average of 4 office blood pressure readings ≥140/90 mm Hg and/or use of antihypertensive medication). Dietary supplements were discontinued for 2 weeks before the study.4,17 Patients were also asked to not smoke18 or eat foods known to affect platelet function (coffee, chocolate, grapes, and alcohol) 48 hours before every sample collection.17
Comparison of aspirin response measured by urinary 11-dehydrothromboxane B2 and VerifyNow aspirin assay in patients with ischemic stroke
2014, Journal of Stroke and Cerebrovascular DiseasesDoes gender have an influence on platelet function and the efficacy of oral antiplatelet therapy?
2012, Interventional Cardiology ClinicsPulmonary Hemorrhage Following Percutaneous Computed Tomography-Guided Lung Biopsy: Retrospective Review of Risk Factors, Including Aspirin Usage
2020, Current Problems in Diagnostic RadiologyCitation Excerpt :The safety of these other antiplatelet agents with respect to bleeding following transthoracic lung biopsy warrants further evaluation. Additionally, no distinction was made in this study between patients taking 81 mg aspirin and those taking 325 mg aspirin, though in a clinical study of 106 healthy subjects, Qayyum et al found near complete suppression of platelet aggregation to arachidonic acid at 81 mg/day, with no incremental suppression at 325 mg/day.15 Another potential limitation of the study is the method by which parenchymal hemorrhage volume was calculated.
Novel Dosing and Monitoring of Aspirin in Infants With Systemic-to–Pulmonary Artery Shunt Physiology: the SOPRANO Study
2023, Journal of Pediatric Pharmacology and TherapeuticsLetters to SIIC
2022, Salud(i)Ciencia
This study was supported by Grant HL-072518 from the National Institutes of Health, Bethesda, Maryland; the Johns Hopkins General Clinical Research Center, Baltimore, Maryland; Grant M01-RR000052 from the National Center for Research Resources; and Grant IMPACT #12492 from Bayer HealthCare LLC, Morristown, New Jersey. Dr. Becker received research support from Bayer HealthCare LLC, Consumer Division; Dr. Faraday received additional research support from NovoNordisk, Princeton, New Jersey.